In Friday’s Wall Street session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares traded at $3.14, up 37.12% from the previous session.
PHAT stock price is now -33.63% away from the 50-day moving average and -68.36% away from the 200-day moving average. The market capitalization of the company currently stands at $219.20M.
With the price target of $23, Cantor Fitzgerald recently initiated with Overweight rating for Phathom Pharmaceuticals Inc (NASDAQ: PHAT). On May 03, 2024, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $24, while ‘Needham’ rates the stock as ‘Buy’
In other news, Parikh Asit, Director bought 5,000 shares of the company’s stock on May 06 ’25. The stock was bought for $13,000 at an average price of $2.60. Upon completion of the transaction, the Director now directly owns 90,500 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 07 ’25, Director Parikh Asit bought 5,000 shares of the business’s stock. A total of $11,984 was incurred on buying the stock at an average price of $2.40. This leaves the insider owning 95,500 shares of the company worth $0.3 million. A total of 44.53% of the company’s stock is owned by insiders.
During the past 12 months, Phathom Pharmaceuticals Inc has had a low of $2.21 and a high of $19.71.
The company reported revenue of $28.52 million for the quarter, compared to $1.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1391.58 percent.
